Taysha Gene Therapies, Inc.

TSHA · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
130
SEC Filings

Business Summary

, Part I, Item 1A. Risk Factors, and Part II, Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations, but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by the words may, might, will, could, would, should, expect, intend, plan, objective, anticipate, believe, estimate, predict, project, potential, continue and ongoing, or the negative of these terms, or other comparable terminology intended to i...

Next Earnings

Q2 FY2026 — expected 2026-08-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionTSHAdiscussed_in_filing Cybersecurity
topic_mentionTSHAdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001193125-26-115202EDGAR109K words
2025-02-262024-12-310000950170-25-027348EDGAR—
2024-03-192023-12-310000950170-24-033484EDGAR—
2023-03-282022-12-310000950170-23-010343EDGAR—
2022-03-312021-12-310001564590-22-012782EDGAR—
2021-03-032020-12-310001564590-21-010433EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-042025-09-300001193125-25-263506EDGAR41K words
2025-08-122025-06-300000950170-25-107010EDGAR—
2025-05-152025-03-310000950170-25-072036EDGAR—
2024-11-132024-09-300000950170-24-126416EDGAR—
2024-08-122024-06-300000950170-24-095082EDGAR—
2024-05-142024-03-310000950170-24-059555EDGAR—
2023-11-142023-09-300000950170-23-063734EDGAR—
2023-08-142023-06-300000950170-23-042089EDGAR—
2023-05-112023-03-310000950170-23-021333EDGAR—
2022-11-082022-09-300001564590-22-036936EDGAR—
2022-08-112022-06-300001564590-22-029155EDGAR—
2022-05-162022-03-310001564590-22-020260EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-190001193125-26-115177EDGAR3K words
2025-11-040001193125-25-263543EDGAR—
2025-10-160001193125-25-241415EDGAR—
2025-10-090001193125-25-235212EDGAR—
2025-10-020001193125-25-227505EDGAR—
2025-08-120001193125-25-178504EDGAR—
2025-06-030001193125-25-133745EDGAR—
2025-05-290001193125-25-130709EDGAR—
2025-05-280001193125-25-129494EDGAR—
2025-05-150001193125-25-120329EDGAR—

130 total filings indexed. 102 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001806310
TickerTSHA
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 1fb19046611c03a5f8939387023b9b8d1299253161afd2b20fb7c343852f9849
parent: 8af4210318812aa96a158b1d2bd19f347326ab15780ab1363c27aa3c796fe39a
content hash: a0db8301b2860020008fae0cddf1ecbf62bb14658bc8831f464e2c72c2151d0c
signed: 2026-04-13T04:47:53.968Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf